About the ABPI

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.

Welcome to the Future of Medicine is available to view through YouTube here and for free third-party use.

A teaser for the experience is available online here.

Gene editing and gene therapies: Gene therapies offer a potential life change for patients with haemophilia B. Around 8,000 people in Europe have haemophilia B, of which 60% live with a severe form of the disease, putting them at risk of bleeds. Gene therapy Phase I/II trials have seen results sufficient to transform the disease into a mild form, while further trials could see a cure. Read more.

Diagnostics sensors: Scientists at Northeastern University in Boston, Massachusetts have been investigating the benefits of using carbon nanosensors. Read more.

3D printing of medicine patches University of Kent PhD students are researching 3D print applications for transdermal drug delivery. Read more.

Media enquiries

+44 (0) 20 7747 7147​​